

BIOMARKERS DISCRIMINATING THE DISCORDANT PHENOTYPES OF X-ADRENOLEUKODYSTROPHY

A research group from CIBER, IDIBELL, Institució Catalana de Recerca I Estudis Avançats and Asociación Española Contra la Leucodistrofia ELA España ha identified novel biomarkers for facilitating diagnostic of variable phenotypes of Xadrenoleucodystrophy

The Need

X-linked adrenoleukodystrophy (X-ALD) is a severe neurometabolic disease that can appear with **several phenotypes** with a broad clinical variable spectrum.

Thus, the identification and validation of biomarkers able to **discriminate** across the phenotypic spectrum is an unmet, urgent need in X-ALD population.

Innovative Aspects

- ✓ Appropriate idenfication of X-ALD phenotypes
- ✓ Improved therapeutic management of the disease:
 - Monitoring response to treatment in clinical trials
 - Information of disease severity and prognosis to define the personalized management of each patient.



Stage of Development:

Analytic validation in human samples from healthy donors and patients

Intellectual Property:

- European patent (EP23382397) application was submitted 16 of March 2023.
- Suitable for international extension (PCT application)

Fig 1. Biomarkers profile in X-ALD patients

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.



Contact details

Consorcio Centro de Investigación Biomédica en Red (CIBER) otc@ciberisciii.es https://www.ciberisciii.es/en

The Solution

Identification of lipid **biomarkers** that can **discriminate among X-ALD phenotypes** in blood and brain samples